Life-saving HIV programmes in Lesotho are at risk of collapse following the loss of US foreign aid, more than 30 NGOs warned ...
In a joint survey by Aidsfonds, GNP+ and the Robert Carr Fund 22% of organizations reported increased experiences of discrimination, including reports of discrimination within healthcare settings, ...
The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...
The U.N.'s Angeli Achrekar reports that many clinics have closed, despite exemptions in the policy. She fears mortality will ...
The withdrawal of USAID funding enacted by Donald Trump is having an immediate impact in poor countries – with reproductive ...
An HIV drug was named “2024 Breakthrough of the Year” by Science Magazine. Biochemistry research from the University of Utah ...
Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir the ...
As of 17 February 2024, UNAIDS had received at least one status report from 52 countries (39 PEPFAR-funded and 13 countries that receive some US support). The 39 countries represent 71% of all ...
Researchers have identified key immunological markers associated with mortality in hospitalised people living with HIV/AIDS.
Despite breakthroughs in HIV treatment and prevention worldwide, critical challenges such as stigma, unequal access and ...
South Africa has more people living with HIV than any other country. Trump's aid freeze has hit hard
In the rural villages of South Africa, U.S. President Donald Trump’s sudden freeze on foreign aid impacts hundreds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback